Atossa Therapeutics, Inc. (ATOS) Stock Price & Analysis
Atossa Therapeutics, Inc. (ATOS) fell 4.77% to USD 2.3 as of July 25, 2026 at 11:14 UTC, according to Nexqual real-time market data.
ATOS last closed at USD 2.41; the session ranged USD 2.26–2.46 on volume of 40,607 shares. Market capitalization is $22.89M, with a 52-week range of USD 1.7–19.35 (NCM). Source: Nexqual, July 25, 2026 at 11:14 UTC.
Key Statistics (as of July 25, 2026 at 11:14 UTC)
| Price | USD 2.3 |
|---|---|
| Change | ▼ 4.77% (down) |
| Previous Close | USD 2.41 |
| Open | USD 2.41 |
| Day Range | USD 2.26 – 2.46 |
| 52-Week Range | USD 1.7 – 19.35 |
| Volume | 40,607 shares |
| Market Cap | $22.89M |
| Exchange | NCM |
Technical Analysis (ATOS)
Nexqual's technical model rates ATOS "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 11:14 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 32.29 (neutral) |
| vs SMA50 | Below (USD 3.28) |
| MACD | -0.19 (negative) |
Analyst Ratings (ATOS)
Wall Street analysts rate ATOS "None" based on 3 analysts, with a mean price target of USD 22 (range USD 20–24), per Nexqual as of July 25, 2026 at 11:14 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 22 |
| High Target | USD 24 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (ATOS)
| EPS Estimate | USD -1.1 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.11 vs est -1.22 ▲ beat |
| 2025-12-31 | USD -1.34 vs est -1.14 ▼ miss |
| 2025-09-30 | USD -1.05 vs est -1 ▼ miss |
| 2025-06-30 | USD -1.05 vs est -0.85 ▼ miss |
Source: Nexqual, July 25, 2026 at 11:14 UTC.
Financials & Fundamentals (ATOS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -78.58% |
| Current Ratio | 4.92 |
| Total Cash | $31.72M |
| Total Debt | $0 |
| Free Cash Flow | $-21.23M |
Source: Nexqual, July 25, 2026 at 11:14 UTC.
Financial Health Score (ATOS)
Nexqual rates Atossa Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 11:14 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $32M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$33M |
| Efficiency | Critical — ROE -79%, ROA -45.5% |
Ownership (ATOS)
| Insider Ownership | +1.85% |
|---|---|
| Institutional Ownership | +16.33% |
| Shares Outstanding | 9.97M |
| Float | 8.58M |
| Short % of Float | +7.79% |
Source: Nexqual, July 25, 2026 at 11:14 UTC.
Leadership (ATOS)
Atossa Therapeutics, Inc. is led by Steven C. Quay FCAP (age 74), Chairman, CEO & President, per Nexqual as of July 25, 2026 at 11:14 UTC.
| Chairman, CEO & President | Steven C. Quay FCAP (age 74) |
|---|---|
| Chief Financial Officer | Mark J. Daniel (age 48) |
| Senior Vice President of Research & Development | Janet Rose Rea MSPH, RAC |
| Senior Vice President of Business Operations | Delly Behen P.H.R. |
Major Backers & Investors (ATOS)
Notable institutional backers of Atossa Therapeutics, Inc. include Ameriprise Financial, Inc., Renaissance Technologies, UBS Group AG, according to Nexqual as of July 25, 2026 at 11:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ameriprise Financial, Inc. | 2.96% |
| Renaissance Technologies | 1.27% |
| UBS Group AG | 1.07% |
| Fidelity | 0.91% |
| Millennium Management | 0.78% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.71% |
| Columbia Threadneedle | 2.64% |
| BlackRock | 1.55% |
| Geode Capital | 1.13% |
| State Street | 0.46% |
Source: Nexqual, July 25, 2026 at 11:14 UTC.
From Atossa Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States.
- Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JAGX | Jaguar Health, Inc. | USD 0.96 | ▼ 27.59% |
| TNXP | Tonix Pharmaceuticals Holding C | USD 9.88 | ▼ 6.7% |
| OCGN | Ocugen, Inc. | USD 1.21 | ▼ 6.2% |
| CTRM | Castor Maritime Inc. | USD 1.87 | ▼ 3.11% |
| SENS | Senseonics Holdings, Inc. | USD 4.86 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 11:14 UTC. This page is informational and not investment advice.